Baseline TGFβ levels (approximately 1 ng/ml in 2% serum supplemented growth media used here) sufficed to induce AP2 binding to the BST2 promoter in 3/3 TGFβ responsive low/intermediate grade breast cancer cell lines. The gene discussed is BST2; the disease is breast carcinoma.